miR-130b在胶质瘤对替莫唑胺耐药中的作用

目的:探讨微小RNA-130b(microRNA-130b,miR-130b)在胶质瘤细胞中的表达及其调控体外胶质瘤细胞对替莫唑胺(temozolomide,TMZ)耐药中的作用。方法:利用RT-qPCR法检测miR-130b在胶质瘤细胞株U251、SHG-44和U87中的表达水平;计算TMZ对不同胶质瘤细胞株(U251、SHG-44和U87)的半数抑制浓度(IC_(50));通过不同浓度梯度的TMZ作用于体外U251细胞,从而获得相对稳定的对TMZ耐药的U251(U251/TMZ resistance,U251/TR)细胞,计算TMZ对U251/TR细胞的IC_(50)及耐药指数(resistance factor,RF);使用miR-130b模拟物(miR-130b mimics)和miR-130b抑制物(miR-130b inhibitor)瞬时转染体外胶质瘤细胞;CCK-8法检测体外胶质瘤细胞的活力;流式细胞术检测胶质瘤细胞凋亡;通过生物信息学工具分析miR-130b可能的靶基因,萤光素酶报告基因实验测定萤光素酶活性;电泳迁移率变动分析检测核因子κB(nuclear factor-κB,NF-κB)的活性;Western blot法测定肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)、Bcl-2、X连锁凋亡抑制蛋白(X-linked inhibitor of apoptosis protein,XIAP)和survivin蛋白在胶质瘤细胞中的表达水平。结果:TMZ对不同胶质瘤细胞株(U251、SHG-44和U87)的IC_(50)分别为54.8、94.8和149.6μmol/L;TMZ对U251/TR细胞的IC_(50)为(446.5±61.3)μmol/L,其RF为8.1;转染miR-130b mimics可明显增强TMZ对U251/TR细胞的生长抑制和凋亡诱导作用;转染miR-130b inhibitor可显著抑制TMZ对U251/TR细胞的生长抑制和凋亡诱导作用;萤光素酶报告基因实验验证TNF-α是miR-130b的直接作用靶点;与mimics NC组相比,转染miR-130b mimics后U251/TR细胞中的NF-κB活性及TNF-α、Bcl-2、XIAP和survivin蛋白表达均明显下调;与inhibitor NC组相比,转染miR-130b inhibitor后U251细胞中的NF-κB活性及TNF-α、Bcl-2、XIAP和survivin蛋白表达均显著上调(P0.05);NF-κB抑制剂Bay 11-7082可增强TMZ对U251/TR细胞凋亡的诱导作用。结论:miR-130b在耐药型胶质瘤细胞中表达下调,并通过靶向调控TNF-α/NF-κB通路增强TMZ对体外胶质瘤细胞的作用。

miR-130b reverses temozolomide resistance in glioma

AIM:To investigate the expression level of microRNA-130b (miR-130b) and the molecular me-chanisms of miR-130b in temozolomide (TMZ)-resistant glioma. METHODS:The relative levels of miR-130b in 3 glioma cell lines (U251, SHG-44 and U87) were assessed by RT-qPCR. The half maximal inhibitory concentration (IC₅₀) of TMZ for the glioma cell lines was analyzed. To establish the TMZ-resistant glioma cell line, U251 cells were exposed to gradually increasing concentrations of TMZ. The IC₅₀ and resistance index (RF) were calculated with GraphPad Prism software. miR-130b-overexpressing U251/TR cells and miR-130b-knockdown U251 cells were established by transient transfection with miR-130b mimics and miR-130b inhibitor, respectively. The viability of the glioma cells was measured by CCK-8 assay. The apoptosis of glioma cells was analyzed by Annexin V/PI apoptosis assay. Bioinformatics software was used to predict the potential target gene of miR-130b, and such prediction was validated by luciferase reporter assay. Electrophoretic mobility shift assay was performed to detect the DNA binding ability of NF-κB. Western blot was used to determine the protein levels of tumor necrosis factor-α (TNF-α), Bcl-2, X-linked inhibitor of apoptosis protein (XIAP) and survivin in the glioma cells. RESULTS:The IC₅₀ values of TMZ for the giloma cell lines U251, SHG-44 and U87 were 54.8, 94.8 and 149.6 μmol/L, respectively. U251/TR cells were approximately 8.1 times resistant to TMZ as compared with its parental cells. Up-regulation of miR-130b significantly reduced the resistance of U251/TR cells to TMZ. On the contrary, down-regulation of miR-130b dramatically increased the tolerance of U251 cells to TMZ. The overexpression of miR-130b promoted apoptosis induced by TMZ in the U251/TR cells. However, the knockdown of miR-130b expression decreased the percentage of apoptotic cells in the U251 cells induced by TMZ (P<0.05). Luciferase reporter assay confirmed that TNF-α was a direct target gene of miR-130b. Knockdown of miR-130b in the U251 cells significantly promoted, while overexpression of miR-130b in the U251/TR cells reduced the DNA binding ability of NF-κB as well as the levels of TNF-α, Bcl-2, XIAP and survivin. Furthermore, NF-κB inhibitor Bay 11-7082 enhanced TMZ-induced apoptosis in the U251/TR cells. CONCLUSION:The expression of miR-130b is significantly decreased in TMZ-resistant glioma cells. miR-130b inhibits resistance of glioma to TMZ by targeting TNF-α/NF-κB pathway.